Acorda gains after resubmitting NDA

Acorda Therapeutics Inc. (NASDAQ:ACOR) rose $3.55 (19%) to $21.89 on Thursday after resubmitting an NDA to FDA for Fampridine-SR to improve walking ability in people with multiple sclerosis (MS). FDA refused to file the NDA in March, citing issues with the formatting of the electronic application and requesting additional information (See BioCentury Extra, Tuesday, March 31, 2009). ...